| Health topic | Type II Diabetes |
|---|---|
| Classification | Diagnosis |
| Scope | Commercialized |
| Manufacturer location |
New Mexico, United States |
Diabetes Mellitus is a growing world-wide problem. Half of the current cases in the developing world go undetected for 5-9 years after onset, leading to irreversible damage. Current diagnostic techniques are invasive and inconvenient due to weak test sensitivity and the need for drawing blood.
The Scout DS is a completely non-invasive device used to detect pre-diabetes and type II diabetes in adults. The patient simply places his or her arm on a portable table device, which accurately measures skin biomarkers such as Advanced Glycation End Products, metabolic and microvascular changes.
This device is particularly beneficial for developing world context because it provides a prompt indication of whether or not a person likely has diabetes without the need for blood.
VeraLight is a privately-funded company that was founded in 2004 in order to develop the Scout DS technology.
Ediger, M. N., Olson, B. P., & Maynard, J. D. (2009). Noninvasive optical screening for diabetes. Journal of Diabetes Science and Technology, 3(4), 776-780.
Cavanaugh, B., Matter, N., Way, J., Maynard, J. Noninvasive Skin Intrinsic Fluorescence Correlates With Degree of Coronary Artery Calcification. VeraLight. PDF available here.
Heubeck, E. (October, 2007). Noninvasive Diabetes Screening Tool Shows Potential. DOC News, Vol. 4 No. 10 7. Link available here.
Scout DS has received CE and Health Canada approval for commercial distribution. It has not yet received FDA approval.
| Authors | Lonny Grafman, Chris Waterguy, Emilio, Kathleen Sienko, Amir Sabet Sarvestani |
|---|---|
| License | CC-BY-SA-3.0 |
| Organizations | Appropedia Foundation, University of Michigan |
| Cite as | Evashiu (2012–2026). "Global Health Medical Device Compendium/VeraLight Scout DS". Appropedia. Retrieved September 30, 2026. |